Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 7, 2025
January 7, 2025
f50a55ce-ff4f-49ce-8c87-908cd129fb0e
Related Documents
Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
Guidance DocumentJanuary 30, 2024Center for Drug Evaluation and Research
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Guidance DocumentFebruary 1, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox